{"groups":[{"description":"GROUP A: Standard of care mobiliation: Bortezomib (1.3 mg/m2) in the evening after completion of mobilization with G-CSF","id":"FG000","title":"A. Standard of Care Mobilization"},{"description":"GROUP B: Bortezomib (1.3 mg/m2) IV on days 4 and 7 (if needed)","id":"FG001","title":"GROUP B: Alternative Mobilization"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawn prior to Velcade"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"17"}],"comment":"1 withdrew consent prior to Velcade infusion\n\n1 removed from protocol prior to Velcade infusioin\n\n1 failed to comply with protocol requirement to come to transplant in 2 months","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}